Common Stock Valuation Ratios (Price Multiples)
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
Merck & Co. Inc., current price multiples
| Merck & Co. Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||
| Current share price (P) | $115.61 | ||||||||||||||||
| No. shares of common stock outstanding | 2,472,392,003 | ||||||||||||||||
| Growth rate (g) | -102.04% | ||||||||||||||||
| Earnings per share (EPS) | $7.38 | ||||||||||||||||
| Next year expected EPS | $-0.15 | ||||||||||||||||
| Operating profit per share | $8.58 | ||||||||||||||||
| Sales per share | $26.29 | ||||||||||||||||
| Book value per share (BVPS) | $21.28 | ||||||||||||||||
| Valuation Ratios (Price Multiples) | |||||||||||||||||
| Price to earnings (P/E) | 15.66 | 91.91 | 25.60 | 17.06 | 36.65 | 45.02 | 21.15 | 21.71 | 19.45 | 17.50 | 25.73 | 30.16 | 27.87 | 27.23 | |||
| Price to operating profit (P/OP) | 13.47 | 25.77 | 21.74 | 12.03 | 28.24 | 35.33 | 17.96 | 23.02 | 10.61 | 22.04 | 22.27 | 28.57 | 22.04 | 21.27 | |||
| Price to sales (P/S) | 4.40 | 6.35 | 5.62 | 2.50 | 5.39 | 14.26 | 6.22 | 6.18 | 2.42 | 5.50 | 3.87 | 9.93 | 6.00 | 3.21 | |||
| Price to book value (P/BV) | 5.43 | — | 22.80 | 6.51 | 2.52 | 35.02 | 7.93 | 7.14 | 1.75 | 2.52 | 3.23 | 6.39 | 7.42 | 5.85 | |||
Based on: 10-K (reporting date: 2025-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Merck & Co. Inc., historical price multiples
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The valuation ratios exhibit considerable fluctuation over the five-year period. Significant increases are observed in 2022 for all ratios, followed by substantial increases in 2023, before declining in 2024 and showing mixed results in 2025. The volatility, particularly in 2023, warrants further investigation to understand the underlying drivers.
- Price to Earnings (P/E)
- The Price to Earnings ratio increased from 14.78 in 2021 to 19.21 in 2022. A dramatic surge occurred in 2023, reaching 893.99, before decreasing substantially to 13.49 in 2024. The ratio then increased to 16.79 in 2025. This extreme volatility suggests significant changes in earnings or investor expectations regarding future earnings.
- Price to Operating Profit (P/OP)
- The Price to Operating Profit ratio followed a similar pattern to the P/E ratio. It rose from 15.39 in 2021 to 15.55 in 2022, then experienced a large increase to 138.56 in 2023. A decline to 11.60 was noted in 2024, followed by an increase to 14.44 in 2025. The correlation with the P/E ratio suggests operating profit is a key driver of valuation changes.
- Price to Sales (P/S)
- The Price to Sales ratio increased steadily from 3.96 in 2021 to 5.43 in 2023. It then decreased to 3.60 in 2024 and rose again to 4.71 in 2025, mirroring the overall trend of initial increases followed by a decline and partial recovery. This indicates that revenue growth or investor perception of revenue potential may be influencing valuation.
- Price to Book Value (P/BV)
- The Price to Book Value ratio increased from 5.05 in 2021 to 8.68 in 2023, indicating a growing premium placed on the company’s net assets. The ratio decreased to 4.99 in 2024 and increased to 5.82 in 2025. This suggests a fluctuating perception of the value of the company’s assets relative to its market price.
The pronounced changes in 2023 across all ratios are particularly noteworthy and likely represent a significant event or shift in market sentiment. The subsequent partial recovery in 2024 and 2025 suggests a stabilization, but continued monitoring is recommended to assess the sustainability of this trend.
AI Ask an analyst for more
Price to Earnings (P/E)
Merck & Co. Inc., historical P/E calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,472,392,003 | 2,526,036,240 | 2,532,643,872 | 2,538,592,467 | 2,527,733,606 | |
| Selected Financial Data (US$) | ||||||
| Net income attributable to Merck & Co., Inc. (in millions) | 18,254) | 17,117) | 365) | 14,519) | 13,049) | |
| Earnings per share (EPS)2 | 7.38 | 6.78 | 0.14 | 5.72 | 5.16 | |
| Share price1, 3 | 123.93 | 91.43 | 128.84 | 109.89 | 76.32 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 16.79 | 13.49 | 893.99 | 19.21 | 14.78 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| AbbVie Inc. | 94.06 | 79.59 | 63.84 | 22.62 | 22.07 | |
| Amgen Inc. | 25.81 | 38.24 | 23.14 | 19.56 | 21.05 | |
| Bristol-Myers Squibb Co. | 17.30 | — | 12.27 | 23.97 | 20.92 | |
| Danaher Corp. | 40.93 | 38.12 | 39.09 | 25.65 | 29.94 | |
| Eli Lilly & Co. | 47.45 | 77.63 | 135.24 | 50.08 | 40.66 | |
| Gilead Sciences Inc. | 21.54 | 296.57 | 16.17 | 22.68 | 12.36 | |
| Johnson & Johnson | 21.66 | 26.92 | 10.73 | 22.97 | 20.93 | |
| Pfizer Inc. | 19.83 | 18.42 | 73.42 | 7.58 | 11.76 | |
| Regeneron Pharmaceuticals Inc. | 18.19 | 17.76 | 25.99 | 19.68 | 8.37 | |
| Thermo Fisher Scientific Inc. | 28.82 | 32.03 | 35.65 | 30.55 | 27.35 | |
| Vertex Pharmaceuticals Inc. | 31.58 | — | 30.42 | 23.02 | 26.55 | |
| P/E Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 28.98 | 45.15 | 32.80 | 20.23 | 19.27 | |
| P/E Ratio, Industry | ||||||
| Health Care | 28.31 | 38.03 | 30.62 | 21.22 | 21.55 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
EPS = Net income attributable to Merck & Co., Inc. ÷ No. shares of common stock outstanding
= 18,254,000,000 ÷ 2,472,392,003 = 7.38
3 Closing price as at the filing date of Merck & Co. Inc. Annual Report.
4 2025 Calculation
P/E ratio = Share price ÷ EPS
= 123.93 ÷ 7.38 = 16.79
5 Click competitor name to see calculations.
The price to earnings (P/E) ratio exhibited significant fluctuations over the five-year period. Initial values indicated a relatively stable valuation, followed by a period of extreme volatility, and a subsequent return towards more moderate levels. The share price and earnings per share (EPS) both demonstrated variability, contributing to the observed P/E ratio movements.
- P/E Ratio Trend
- The P/E ratio began at 14.78 in 2021, increasing to 19.21 in 2022. A dramatic surge occurred in 2023, reaching 893.99, before declining substantially to 13.49 in 2024. The ratio then increased again to 16.79 in 2025. This pattern suggests a period of substantial market re-evaluation in 2023, potentially driven by unusual earnings figures.
- Share Price Behavior
- The share price increased from US$76.32 in 2021 to US$109.89 in 2022, and further to US$128.84 in 2023. A notable decrease was observed in 2024, with the price falling to US$91.43, followed by a recovery to US$123.93 in 2025. This indicates periods of investor optimism and pessimism influencing the stock’s valuation.
- Earnings Per Share (EPS) Analysis
- EPS showed an initial increase from US$5.16 in 2021 to US$5.72 in 2022. A significant drop occurred in 2023, with EPS falling to US$0.14. EPS then rebounded strongly to US$6.78 in 2024 and continued to rise to US$7.38 in 2025. The substantial decline in EPS in 2023 is a key driver of the exceptionally high P/E ratio observed in that year.
The volatility in the P/E ratio is largely attributable to the significant fluctuations in EPS, particularly the sharp decrease in 2023. While the share price also experienced changes, the impact of EPS on the P/E ratio was more pronounced. The return to more moderate P/E levels in 2024 and 2025 coincides with the recovery in EPS, suggesting a re-alignment between earnings and market valuation.
AI Ask an analyst for more
Price to Operating Profit (P/OP)
Merck & Co. Inc., historical P/OP calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,472,392,003 | 2,526,036,240 | 2,532,643,872 | 2,538,592,467 | 2,527,733,606 | |
| Selected Financial Data (US$) | ||||||
| Operating income (in millions) | 21,218) | 19,912) | 2,355) | 17,945) | 12,538) | |
| Operating profit per share2 | 8.58 | 7.88 | 0.93 | 7.07 | 4.96 | |
| Share price1, 3 | 123.93 | 91.43 | 128.84 | 109.89 | 76.32 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 14.44 | 11.60 | 138.56 | 15.55 | 15.39 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| AbbVie Inc. | 26.37 | 37.26 | 24.34 | 14.78 | 14.21 | |
| Amgen Inc. | 21.92 | 21.55 | 19.69 | 13.40 | 16.24 | |
| Bristol-Myers Squibb Co. | 12.20 | — | 13.53 | 18.29 | 19.84 | |
| Danaher Corp. | 31.54 | 30.56 | 35.64 | 20.97 | 25.14 | |
| Eli Lilly & Co. | 37.24 | 63.73 | 109.75 | 43.88 | 35.70 | |
| Gilead Sciences Inc. | 18.29 | 85.65 | 12.05 | 14.21 | 7.76 | |
| Johnson & Johnson | 22.95 | 18.20 | 17.78 | 17.62 | 18.68 | |
| Pfizer Inc. | 10.82 | 11.92 | 121.63 | 6.64 | 12.74 | |
| Regeneron Pharmaceuticals Inc. | 22.90 | 19.63 | 25.39 | 18.01 | 7.55 | |
| Thermo Fisher Scientific Inc. | 24.94 | 27.65 | 31.16 | 25.30 | 21.07 | |
| Vertex Pharmaceuticals Inc. | 29.92 | — | 28.74 | 17.75 | 22.35 | |
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 22.92 | 31.13 | 32.68 | 15.94 | 16.68 | |
| P/OP Ratio, Industry | ||||||
| Health Care | 22.12 | 26.90 | 27.48 | 16.58 | 18.20 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 21,218,000,000 ÷ 2,472,392,003 = 8.58
3 Closing price as at the filing date of Merck & Co. Inc. Annual Report.
4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 123.93 ÷ 8.58 = 14.44
5 Click competitor name to see calculations.
The price to operating profit (P/OP) ratio exhibited significant fluctuations over the five-year period. Initial values were relatively stable, followed by a substantial increase and subsequent decline, concluding with a return towards earlier levels. This analysis details the observed trends and potential implications.
- Share Price
- The share price demonstrated an increasing trend from 2021 to 2023, rising from US$76.32 to US$128.84. A notable decrease occurred in 2024, falling to US$91.43, before recovering to US$123.93 in 2025. This suggests periods of investor optimism followed by correction and subsequent renewed confidence.
- Operating Profit per Share
- Operating profit per share increased from US$4.96 in 2021 to US$7.07 in 2022. A substantial decline was observed in 2023, with operating profit per share falling to US$0.93. This was followed by a recovery to US$7.88 in 2024 and a further increase to US$8.58 in 2025. The volatility in operating profit per share significantly impacted the P/OP ratio.
- Price to Operating Profit (P/OP)
- The P/OP ratio remained relatively consistent between 2021 and 2022, at 15.39 and 15.55 respectively. A dramatic increase occurred in 2023, reaching 138.56, driven primarily by the sharp decrease in operating profit per share. The ratio then decreased substantially in 2024 to 11.60, coinciding with the recovery in operating profit per share. In 2025, the P/OP ratio rose to 14.44, indicating a moderate increase from the previous year but remaining below the peak observed in 2023. The large fluctuation in the P/OP ratio suggests a high degree of sensitivity to changes in operating profitability.
The significant divergence in the P/OP ratio in 2023 warrants further investigation. The substantial increase suggests the market may have anticipated a temporary decline in operating profit, or that other factors influenced the share price. The subsequent decline in 2024, coupled with the recovery in operating profit, indicates a re-evaluation by investors. The final value in 2025 suggests a stabilization, though still exhibiting volatility compared to the initial years of the period.
AI Ask an analyst for more
Price to Sales (P/S)
Merck & Co. Inc., historical P/S calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,472,392,003 | 2,526,036,240 | 2,532,643,872 | 2,538,592,467 | 2,527,733,606 | |
| Selected Financial Data (US$) | ||||||
| Sales (in millions) | 65,011) | 64,168) | 60,115) | 59,283) | 48,704) | |
| Sales per share2 | 26.29 | 25.40 | 23.74 | 23.35 | 19.27 | |
| Share price1, 3 | 123.93 | 91.43 | 128.84 | 109.89 | 76.32 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 4.71 | 3.60 | 5.43 | 4.71 | 3.96 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| AbbVie Inc. | 6.50 | 6.04 | 5.72 | 4.61 | 4.53 | |
| Amgen Inc. | 5.66 | 4.88 | 5.78 | 5.17 | 5.10 | |
| Bristol-Myers Squibb Co. | 2.53 | 2.36 | 2.19 | 3.29 | 3.16 | |
| Danaher Corp. | 6.02 | 6.23 | 7.76 | 5.79 | 6.37 | |
| Eli Lilly & Co. | 15.03 | 18.25 | 20.77 | 10.96 | 8.01 | |
| Gilead Sciences Inc. | 6.34 | 4.98 | 3.40 | 3.86 | 2.85 | |
| Johnson & Johnson | 6.16 | 4.26 | 4.43 | 4.34 | 4.66 | |
| Pfizer Inc. | 2.46 | 2.32 | 2.61 | 2.35 | 3.15 | |
| Regeneron Pharmaceuticals Inc. | 5.71 | 5.52 | 7.84 | 7.01 | 4.20 | |
| Thermo Fisher Scientific Inc. | 4.34 | 4.73 | 4.99 | 4.73 | 5.39 | |
| Vertex Pharmaceuticals Inc. | 10.40 | 10.78 | 11.16 | 8.56 | 8.21 | |
| P/S Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.24 | 5.55 | 5.89 | 4.56 | 4.50 | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.34 | 3.36 | 3.52 | 3.11 | 3.28 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
Sales per share = Sales ÷ No. shares of common stock outstanding
= 65,011,000,000 ÷ 2,472,392,003 = 26.29
3 Closing price as at the filing date of Merck & Co. Inc. Annual Report.
4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= 123.93 ÷ 26.29 = 4.71
5 Click competitor name to see calculations.
The price to sales ratio exhibited a generally increasing trend from 2021 to 2023, followed by a significant decrease in 2024, and a subsequent recovery in 2025. This movement occurred alongside fluctuations in both share price and sales per share.
- Price to Sales Ratio (P/S)
- The P/S ratio increased from 3.96 in 2021 to 5.43 in 2023, indicating investors were willing to pay a progressively higher price for each dollar of sales. This could reflect increasing investor confidence or expectations of future growth. However, the ratio declined sharply to 3.60 in 2024, suggesting a decrease in investor enthusiasm or a reassessment of the company’s sales potential. The ratio then rebounded to 4.71 in 2025, approaching the level observed in 2022.
- Share Price
- The share price demonstrated an increase from US$76.32 in 2021 to US$128.84 in 2023. This growth likely contributed to the rising P/S ratio during this period. A substantial decrease to US$91.43 occurred in 2024, coinciding with the drop in the P/S ratio. The share price recovered to US$123.93 in 2025, mirroring the partial recovery in the P/S ratio.
- Sales per Share
- Sales per share showed a consistent upward trend throughout the observed period, increasing from US$19.27 in 2021 to US$26.29 in 2025. This indicates a steady growth in the company’s revenue generation on a per-share basis. While sales per share increased in 2024, the decrease in share price was more pronounced, resulting in the lower P/S ratio for that year.
The interplay between share price and sales per share suggests that investor sentiment and market conditions significantly influence the P/S ratio. The consistent growth in sales per share provides a positive underlying trend, but the P/S ratio’s volatility indicates that external factors and investor perceptions play a crucial role in valuation.
AI Ask an analyst for more
Price to Book Value (P/BV)
Merck & Co. Inc., historical P/BV calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,472,392,003 | 2,526,036,240 | 2,532,643,872 | 2,538,592,467 | 2,527,733,606 | |
| Selected Financial Data (US$) | ||||||
| Total Merck & Co., Inc. stockholders’ equity (in millions) | 52,606) | 46,313) | 37,581) | 45,991) | 38,184) | |
| Book value per share (BVPS)2 | 21.28 | 18.33 | 14.84 | 18.12 | 15.11 | |
| Share price1, 3 | 123.93 | 91.43 | 128.84 | 109.89 | 76.32 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 5.82 | 4.99 | 8.68 | 6.07 | 5.05 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| AbbVie Inc. | — | 102.40 | 29.97 | 15.52 | 16.53 | |
| Amgen Inc. | 22.99 | 26.61 | 24.94 | 35.01 | 18.51 | |
| Bristol-Myers Squibb Co. | 6.61 | 6.98 | 3.35 | 4.88 | 4.07 | |
| Danaher Corp. | 2.82 | 3.00 | 3.47 | 3.64 | 4.16 | |
| Eli Lilly & Co. | 36.91 | 57.93 | 65.80 | 29.36 | 25.28 | |
| Gilead Sciences Inc. | 8.07 | 7.36 | 4.01 | 4.90 | 3.65 | |
| Johnson & Johnson | 7.12 | 5.30 | 5.48 | 5.37 | 5.90 | |
| Pfizer Inc. | 1.78 | 1.68 | 1.75 | 2.48 | 3.35 | |
| Regeneron Pharmaceuticals Inc. | 2.62 | 2.67 | 3.96 | 3.77 | 3.60 | |
| Thermo Fisher Scientific Inc. | 3.62 | 4.09 | 4.57 | 4.83 | 5.18 | |
| Vertex Pharmaceuticals Inc. | 6.69 | 7.24 | 6.26 | 5.50 | 6.16 | |
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 7.72 | 7.03 | 6.77 | 5.66 | 5.72 | |
| P/BV Ratio, Industry | ||||||
| Health Care | 6.08 | 5.99 | 5.94 | 5.26 | 5.48 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 2025 Calculation
BVPS = Total Merck & Co., Inc. stockholders’ equity ÷ No. shares of common stock outstanding
= 52,606,000,000 ÷ 2,472,392,003 = 21.28
3 Closing price as at the filing date of Merck & Co. Inc. Annual Report.
4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= 123.93 ÷ 21.28 = 5.82
5 Click competitor name to see calculations.
The price to book value ratio exhibited considerable fluctuation over the five-year period. Initial values indicated a moderate valuation, followed by a period of increasing valuation, and then a subsequent decline before stabilizing. A detailed examination of the ratio’s behavior is presented below.
- Price to Book Value (P/BV) Trend
- The P/BV ratio began at 5.05 in 2021 and increased to 6.07 in 2022, suggesting a growing investor confidence in the company’s ability to generate value relative to its net asset value. This upward trend continued into 2023, with the ratio reaching a peak of 8.68. However, 2024 witnessed a substantial decrease to 4.99, falling below the initial 2021 level. The ratio partially recovered in 2025, closing at 5.82.
- Share Price and Book Value Per Share Relationship
- The share price demonstrated an initial increase from US$76.32 in 2021 to US$109.89 in 2022, and further to US$128.84 in 2023, mirroring the rise in the P/BV ratio. The subsequent drop in share price to US$91.43 in 2024 contributed to the decline in the P/BV ratio. A partial recovery in share price to US$123.93 in 2025 accompanied a modest increase in the P/BV ratio.
- Book value per share also showed an increasing trend, rising from US$15.11 in 2021 to US$18.12 in 2022, then decreasing to US$14.84 in 2023, and increasing again to US$18.33 in 2024, before reaching US$21.28 in 2025. The interplay between share price and book value per share significantly influenced the P/BV ratio’s movements.
The volatility in the P/BV ratio suggests that market perceptions of the company’s value relative to its book value have been subject to change. The peak in 2023 may indicate a period of heightened optimism, while the decline in 2024 could reflect concerns about future performance or broader market conditions. The stabilization in 2025 suggests a potential re-evaluation of the company’s prospects.
AI Ask an analyst for more